Faeth Therapeutics, Inc. Stock Analysis & AI Score
Faeth Therapeutics, Inc. (FTH) has an ST Score of 53.8 (B-), driven by its Financial Strength (A+) and held back by its Profitability (F). Analysts rate it Buy with a $58.50 price target (+101.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Faeth Therapeutics, Inc. (FTH) has an ST Score of 53.8 (B-), driven by its Financial Strength (A+) and held back by its Profitability (F). Analysts rate it Buy with a $58.50 price target (+101.4% upside).
- Strongest
- Financial StrengthA+
- Weakest
- ProfitabilityF
All factor grades
- Financial StrengthA+
- ForecastA
- MomentumA-
- ValuationB-
- GrowthC+
- ProfitabilityF
- Piotroski2/9
Contact
FTH stock: frequently asked questions
What is FTH's ST Score?
Faeth Therapeutics, Inc. (FTH) has an ST Score of 53.8 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is FTH a buy, hold, or sell?
Analysts rate FTH a Buy, with a price target of $58.50 (+101.4% vs the current price). Our ST Score grades it B- (53.8/100). The ST Score is a data-driven signal, not a recommendation.
What are FTH's factor grades?
Valuation B-, Profitability F, Financial Strength A+, Momentum A-, Growth C+, Forecast A.
What is FTH's valuation grade?
Faeth Therapeutics, Inc. (FTH) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is FTH's growth grade?
Faeth Therapeutics, Inc. (FTH) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is FTH's profitability grade?
Faeth Therapeutics, Inc. (FTH) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is FTH's financial strength grade?
Faeth Therapeutics, Inc. (FTH) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for FTH?
The average analyst price target for Faeth Therapeutics, Inc. (FTH) is $58.50 from 5 analysts, which is +101.4% versus the recent price of $29.05.
What is FTH's Piotroski score?
Faeth Therapeutics, Inc. (FTH) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.